Aurobindo Receives FDA Approval for Sevelamer Carbonate Tablets, 800 mg
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Sevelamer Carbonate Tablets, 800 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Sevelamer Carbonate Tablets, 800 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug Renvela®. Sevelamer Carbonate is a […]
Aurobindo Receives FDA Approval for Sevelamer Carbonate Tablets, 800 mg Read More »